key: cord-0841084-0ai7guzw
authors: Wang, Ralph C.; Murphy, Charles E.; Kornblith, Aaron E.; Hohenstein, Nicole A.; Carter, Cornelius M.; Wong, Angela H.K.; Kurtz, Theodore; Kohn, Michael A.
title: SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021
date: 2022-02-02
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2022.01.055
sha: 1e7c4b3f33f8f9783deaa4f4e54110129882920a
doc_id: 841084
cord_uid: 0ai7guzw

BACKGROUND: Emergency department (ED) workers have an increased seroprevalence of SARS-CoV-2 antibodies. However, breakthrough infections in ED workers have led to a reduced workforce within a strained healthcare system. By measuring levels of IgG antibodies to the SARS-CoV-2 nucleocapsid and spike antigens in ED workers, we determined the incidence of infection and described the course of antibody levels. We also measured the antibody response to vaccination and examined factors associated with immunogenicity. METHODS: We conducted a prospective cohort study of ED workers conducted at a single ED from September 2020–April 2021. IgG antibodies to the SARS-CoV-2 nucleocapsid antigen were measured at baseline, 3, and 6 months, and IgG antibodies to the SARS-CoV-2 spike antigen were measured at 6 months. RESULTS: At baseline, we found 5 out of 139 (3.6%) participants with prior infection. At 6 months, 4 of the 5 had antibody results below the test manufacturer's positivity threshold. We identified one incident case of SARS-COV-2 infection out of 130 seronegative participants (0.8%, 95% CI 0.02–4.2%). In 131 vaccinated participants (125 BNT162b2, 6 mRNA-1273), 131 tested positive for anti-spike antibodies. We identified predictors of anti-spike antibody levels: time since vaccination, prior COVID-19 infection, age, and vaccine type. Each additional week since vaccination was associated with an 11.1% decrease in anti-spike antibody levels. (95% CI 6.2–15.8%). CONCLUSION: ED workers experienced a low incidence of SARS-CoV-2 infection and developed antibodies in response to vaccines and prior infection. Antibody levels decreased markedly with time since infection or vaccination.

Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, researchers have estimated the cumulative incidence of infection by measuring IgG antibodies to SARS-COV-2. 1,2 Based on studies of anti-SARS-CoV-2 seroprevalence, frontline healthcare workers have an increased risk of infection as compared to non-healthcare workers. 3, 4 Emergency department (ED) workers may be particularly vulnerable as they provide care for undifferentiated patients whose COVID-19 status is unknown and perform high-risk procedures such as nasopharyngeal swab testing, endotracheal intubation, and cardiopulmonary resuscitation. Despite initial studies suggesting high seroprevalence, 5 it is unclear if ED health care workers were at increased risk for contracting COVID-19 through the pandemic. 6 In addition to their use in estimating the incidence of COVID-19, anti-SARS-CoV-2 antibody assays have also been used in the development of COVID-19 vaccines. Phase 1 trials of the BNT162b2 J o u r n a l P r e -p r o o f (Pfizer-BioNTech) vaccine used receptor-binding domain (RBD) or S1 IgG assays to measure vaccine immunogenicity. 7 In December 2020, ED healthcare workers were offered the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) mRNA vaccines, which were both found to have high vaccine efficacy (greater than 90%) to prevent symptomatic COVID-19 infection. 8, 9 In the summer of 2021, breakthrough COVID infections, confirmed by SARS-COV-2 PCR testing, in those fully vaccinated have been increasingly reported, including among frontline healthcare workers. [10] [11] [12] Breakthrough infections in frontline healthcare workers have led to a reduced workforce within an already strained healthcare system. As variants (Delta and Omicron) have spread throughout the United States, concerns about reduced vaccine efficacy have arisen. 13, 14 Despite initial reports of the durable protection, 15 it now appears that immunity may wane.

By measuring levels of IgG antibodies to the SARS-CoV-2 nucleocapsid and spike antigens during the COVID-19 pandemic in a cohort of ED workers, we sought to determine the cumulative incidence of infection and describe the longitudinal course of antibody levels in those who were infected. Also, as ED healthcare workers received COVID-19 vaccinations, we measured post-vaccination antibody levels to examine factors associated with immunogenicity, including time since vaccination, age, and prior COVID-19 infection. We hypothesized that time since vaccination is independently associated with reduced antibody levels.

technicians. This study was performed in accordance with the STROBE guidelines and was approved by the local institutional review board.

Participants were enrolled voluntarily as previous described. 6 Briefly, we enrolled ED healthcare workers (attending physicians, resident physicians, nurses, nurse practitioners, physician assistants, patient care technicians, and pharmacists). We excluded healthcare workers who were pregnant, immune compromised, or who were planning to move or unable to attend study visits. Participants were recruited by email and informed consent was obtained electronically.

The original intent of the study was to measure anti-nucleocapsid antibody levels to determine the incidence of COVID-19 infection among ED healthcare workers. Participants attended three study visits:

Baseline (September 2020); three-months (December2020); and six-months -March 2021. At each study visit, participants were interviewed and underwent venipuncture. All blood specimens were tested for immunoglobulin G (IgG) antibodies to the SARS-CoV-2 nucleocapsid antigen with a chemiluminescent immunoassay (Abbott Architect SARS-CoV-2 IgG; Abbott Laboratories, Abbott Park, IL) to identify prior infection with SARS-CoV-2. 16 At baseline and 3-months, specimens that were positive for the antinucleocapsid antibody were also tested with a different chemiluminescent immunoassay for anti-spike antibodies (Diasorin Liaison SARS-CoV-2 S1/S2 IgG; Diasorin Inc., Cypress, CA) to minimize false positives. We obtained both qualitative and quantitative results for all antibody assays. The 

The survey obtained at each visit included clinical variables about exposure to COVID-19 patients and risk factors for community-based exposure. We also surveyed participants regarding vaccination type and dates of vaccination.

Continuous participant characteristics were summarized in the demographics and results tables with means and standard deviations (SDs) or medians and interquartile ranges (IQR) as appropriate.

Categorical variables were presented as frequencies and percentages.

To study the pattern of quantitative anti-nucleocapsid antibody levels over time, we identified all participants who had an anti-nucleocapsid antibody level above the MHRA threshold at any of the 3 study visits and presented their sequential levels along with additional details. We also used the cross-sectional 6-month data to compare weeks since second vaccine dose and anti-spike antibody levels. For this analysis, we used linear regression with the natural logarithm of the anti-spike antibody level as the J o u r n a l P r e -p r o o f outcome and weeks since second vaccine dose, age in decades, prior COVID-19 infection, and vaccine type as independent variables (based on a review of the prior literature). 20, 21 We excluded participants who had not yet had their second vaccine dose by their 6-month visit. We calculated the percentage change in antibody level for a 1-unit increase in the predictor as (exp( ) -1) x 100%, where is the linear regression coefficient. All analyses were conducted with STATA MP (version 16). The sample size was initially calculated for the baseline study and was described previously. 6

Our study enrolled 139 of 360 (38.6%) eligible ED healthcare workers starting September 1, 2020. All 139 participants provided baseline demographic data, survey answers, and venous blood specimens. Of the 139 participants, 90 (64.7%) were female, 88 (63.3%) white, with a median age of 36 (IQR 27-61) years. Most of the participants were nurses, attending physicians, or resident physicians.

97% of participants at baseline and 98% at 3 and 6 months reported using N95 respirators for high-risk patients, and 92-94% reported contact with at least one COVID-positive patient at each timepoint, while 50% reported contact with >10 COVID-positive patients (Table 1 ). In total, five participants (3.6%) were lost to 6-month follow-up due to the following: administrative leave (n =1), graduating residency and leaving the area (n = 1), no longer on staff (n = 2), and no response (n = 1).

Antibody results from the first study visit were reported previously. 6 During the first study visit, we identified 4/139 (2.9%) who were positive for anti-nucleocapsid antibodies based on the manufacturer's threshold of 1.4 AU. (Table 2 , Participants A-D) One participant ( Table 2 . Participants with confirmed infection had steep decreases in the quantitative antibody measurement after infection.

But these 4 participants showed lower but persistently elevated measurements. (Figure 1 ) One of the four (Participant W) had an above-threshold anti-nucleocapsid antibody measurement at 6 months after 2 nearthreshold levels at baseline and 3 months, while the anti-spike antibody results were negative. This participant was able to obtain pre-COVID plasma for testing, and it had a similarly elevated antinucleocapsid antibody measurement. We suspect this individual's elevated antibodies were due to prior infection with an endemic coronavirus and cross-reacting antibodies. Table 3 ) Each additional week since vaccination was associated with an 11.1% decrease in anti-spike antibody levels. (95% CI 6.2 to 15.8%) and each additional decade in age was associated with a 10.8% decrease. Prior infection was associated with 78% higher antibody levels on univariable analysis and almost 3 times the level on multivariable analysis. However, only 5 of the 131 participants included in this analysis had been infected.

We conducted a prospective cohort study evaluating anti-SARS-CoV-2 antibodies in ED healthcare workers from September 2020 to April 2021, spanning a total of six months. Overall, we observed a low baseline seroprevalence and identified only one incident case during our study period.

Also, we observed a pattern of decline in anti-nucleocapsid antibodies in those with confirmed COVID-19 infection such that 4 out of 5 participants classified as seropositive at baseline had below-threshold results at the end of the study period.

Previous research on risk of COVID-19 infection in frontline providers has been mixed, with some studies finding substantially higher rates of infection relative to the surrounding community. 3, 4, 6, 22 One factor that may contribute to our study's low incidence is that nearly all participants (98%) reported routinely using N95 respirators. Another factor may be the low incidence of COVID-19 in the community served. Since the beginning of the pandemic, approximately 4.1 % of our community has been infected, similar to our observed seroprevalence.

Essentially all of our cohort was vaccinated during the study period and had positive anti-spike antibodies post-vaccination. However, we determined that increasing time since vaccination was significantly associated with lower antibody levels, which may have implications for immunity in healthcare workers. In a recent case-control study, reduced antibody levels were associated with breakthrough infections in those who were vaccinated. 10 infection had higher antibody titers compared to healthcare workers who were COVID-19 naïve, 24,25 and those finding that older age is associated with a less robust antibody response to vaccination. 24 Our study is unique because we obtained both the anti-nucleocapsid antibody binary result (using manufacturer threshold) and the quantitative result. For those participants with a positive antinucleocapsid antibody or those vaccinated, we then obtained anti-spike antibody qualitative and quantitative results. Our dual antibody measurement strategy allowed us to differentiate prior COVID-19 infection (both positive) compared to vaccination (only anti-spike positive). We observed that, regardless of participant factors, including previous COVID-19 infection or vaccination, antibody levels decreased over time. The waning of antibody levels has important implication for population-based surveillance and research, including an understanding of the time interval required to assess whether participants have had previous infection. For example, if we only obtain binary results every 6 months, we will miss participants who were infected (e.g., Table 2 , Participant E).

Our study is subject to several limitations. We did not measure neutralizing antibodies or correlates of T-cell immunity. Instead, we used multiple commercial assays, which have been shown to predict neutralization activity against SARS-CoV-2. 19 Also, previous research suggests that neutralizing antibody levels are highly predictive of immune protection against symptomatic infection. 10, 23 In addition, few study participants had evidence of COVID infection. Our study was conducted at a single center with a low community prevalence of COVID-19, and the low sero-incidence may not be generalizable to other ED workers serving higher prevalence communities. This highlights the need for future multi-center studies in broader populations.

In our study, even prior to vaccination, the risk of ED healthcare workers contracting SARS-CoV-2 was relatively low. We found that antibody levels decrease markedly over the 6-9 months after infection or vaccination and that the antibody response to vaccination appears to be inversely related to age. The clinical implications of these findings are not fully understood but suggest the need for vigilant surveillance of healthcare workers for evidence of waning immunity to infection and severe disease.

Funding: This study was funded by the University of California Office of the President. The funder did not have a role in study design, analysis, or reporting. J o u r n a l P r e -p r o o f 

Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults

Antibody tests for identification of current and past infection with SARS-CoV-2

Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in New Jersey

Antibodies in Emergency Medicine Healthcare Workers

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. medRxiv

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Confronting the Delta Variant of SARS-CoV-2

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Performance Characteristics of the Abbott Architect 18

Anti-SARS-CoV-2 Antibody Levels Measured by the

CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity

Antibodies in Persons with Mild Covid-19

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers

J o u r n a l P r e -p r o o f